Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

ElsevierVolume 175, August 2023, Pages 1-7Gynecologic OncologyAuthor links open overlay panel, , , , , , , Highlights•

This study used the NFOSI-18, which has more questions on relevant side effects of rucaparib than other QOL measures.

On the NFOSI-18, patients receiving rucaparib had a higher risk of deterioration than those receiving the placebo.

Patients receiving rucaparib reported high-moderate side effect bother on the FACT item GP5 approximately 20% of the time.

AbstractPurpose

To compare NFOSI-18 Disease Related Symptoms – Physical (DRSsingle bondP), Total score, and side effect bother between maintenance rucaparib (600 mg twice daily) vs. placebo in the phase III ARIEL3 trial.

Methods

ARIEL3 (NCT01968213) included patients with ovarian carcinoma who responded to second-line or later platinum-based chemotherapy. The NFOSI-18 DRS-P and Total scales were secondary endpoints. The NFOSI-18 contains a side effect impact item (GP5): “I am bothered by side effects of treatment.” We compared treatment arms on change from baseline of DRS-P and Total scores using mixed models with repeated measures (MRMM). Time to first and confirmed deterioration of NFOSI-18 DRS-P and Total scales were analyzed using Cox regression. We also calculated the proportion of patients reporting moderate to high side effect bother on GP5.

Results

In the intention-to-treat (ITT) cohort, mean change from baseline favored the placebo. Compared to placebo, rucaparib was associated with higher risk of deterioration [e.g., 4-point deteriorator definition hazard ratio (HR): 1.85; 95% CI: 1.46, 2.36; median time to first deterioration on DRSsingle bondP: 1.9 vs. 7.0 months]. Confirmed deterioration results resembled those for first deterioration. Proportions of patients reporting moderate/high side effect bother on GP5 fluctuated around 20% across treatment cycles. Results in BRCA mutant and homologous recombination deficient cohorts were generally similar to those from the ITT cohort.

Conclusion

This placebo-controlled study in the maintenance therapy setting provides a unique view of the impact of PARP inhibition on the patient-reported outcomes that are commonly used in ovarian cancer clinical trials. Information regarding the adverse side effect impact of PARP inhibitors should be weighed against their clinical benefit.

Keywords

PARP-inhibitors

Rucaparib

ARIEL3 trial

Quality of life

Patient reported outcome

View full text

© 2023 Elsevier Inc. All rights reserved.

留言 (0)

沒有登入
gif